Clinical and virological characteristics of lamivudine resistance in chronic hepatitis B patients: A single center experience

Journal of Medical Virology

Volumn 75, Issue 3, 2005, Pages 391-398

  Sun, Jian ^a   Wang, Zhanhui ^a   Ma, Shiwu ^a   Zeng, Guobing ^a   Zhou, Zhiyong ^a   Luo, Kangxian ^a   Hou, Jinlin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

Author keywords

Drug resistance; Hepatitis B virus; Lamivudine; Mutant; Polymerase gene

Indexed keywords

ALANINE AMINOTRANSFERASE; HEPATITIS B(E) ANTIGEN; LAMIVUDINE; VIRUS DNA;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; CHINA; DISEASE EXACERBATION; FEMALE; FOLLOW UP; GENETIC TRANSFECTION; GENOTYPE; HEPATITIS B; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; MUTANT; NONHUMAN; NUCLEOTIDE SEQUENCE; PATIENT MONITORING; VIRUS REPLICATION; WILD TYPE;

ADOLESCENT; ADULT; AGED; ALANINE TRANSAMINASE; AMINO ACID SEQUENCE; AMINO ACID SUBSTITUTION; CHILD; CHINA; DNA, VIRAL; DRUG RESISTANCE, VIRAL; FEMALE; GENOTYPE; HEPATITIS B E ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; MOLECULAR SEQUENCE DATA; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; VIRUS REPLICATION;

HEPATITIS B VIRUS;

EID: 12944249327     PISSN: 01466615     EISSN: None     Source Type: Journal    
DOI: 10.1002/jmv.20281     Document Type: Article

References (40)

1. Allen MI, Deslauriers M, Andrews CW, Tipples GA, Walters KA, Tyrrell DL, Brown N, Condreay LD. 1998. Identification and characterization of mutations in the hepatitis B virus resistant to lamivudine. Lamivudine clinical Investigation Group. Hepatology 27:1670-1677.
2. Allen MI, Gauthier J, DesLauriers M, Bourne EJ, Carrick KM, Baldanti F, Ross LL, Lutz MW, Condreay LD. 1999. Two sensitive PCR-based methods for detection of hepatitis B virus variants associated with reduced susceptibility to lamivudine. J Clin Microbiol 37:3338-3347.
3. Alter MJ, Mast EE. 1994. The epidemiology of viral hepatitis in the United States. Gastroenterol Clin North Am 23:437-455.
4. Beasley RP. 1998. The major etiology of hepatocellular carcinoma. Cancer 61:1942-1956.
5. Chang TT, Lai CL, Liaw YF, Guan R, Lim SG, Lee CM, Ng KY. 2000. Incremental increases in HBeAg seroconversion and continued ALT normalization in Asian chronic HBV (CHB) patients treated with lamivudine for four years [abstract]. Antivir Ther 5:44.
6. Dienstag J, Perillo R, Schiff E, Bartholomew M, Vicary C, Rubin M. 1995. A preliminary trial of lamivudine for chronic hepatitis B infection. N Engl J Med 333:1657-1661.
7. Dienstag JL, Schiff ER, Wright TL, Perrilo RP, Kann HW, Goodman Z, Crowther L, Condreay LD, Woessner M, Rubin M, Brown NA. 1999a. Lamivudine as initial treatment for chronic hepatitis B in the United States. N Engl J Med 341:1256-1263.
8. Dienstag JL, Schiff ER, Mitchell M, Casey DE, Jr., Gitlin N, Lissoos T, Gelb LD, Condreay L, Crowther L, Rubin M, Brown N. 1999b. Extended lamivudine retreatment for chronic hepatitis B: Maintenance of viral suppression after discontinuation of therapy. Hepatology 30:1082-1087.
9. Dienstag JL, Cianciara J, Karayalcin S, Kowdley KV, Willems B, Plisek S, Woessner M, Gardner S, Schiff E. 2003. Durability of serologic response after lamivudine treatment of chronic hepatitis B. Hepatology 37:748-755.
10. Fu L, Cheng YC. 1998. Role of additional mutations outside the YMDD motif of hepatitis B virus polym erase in L(-)SddC (3TC) resistance. Biochem Pharmacol 55:1567-1572.
11. Fu L, Wu X, Kong YY, Wang Y. 1996. Regulation of Hepatitis B Virus gene expression by its two enhancers. Sheng Wu Hua Xue Yu Sheng Wu Wu Li Xue Bao (Shanghai) 28:590-599.
12. He ML, Wu J, Chen Y, Lin MC, Lau GK, Rung HF. 2002. A new and sensitive method for the quantification of HBV cccDNA by real-time PCR. Biochem Biophy Res Commun 295:1102-1107.
13. Honkoop P, Niesters HG, de Man RA, Osterhaus AD, Schalm SW. 1997. Lamivudine resistance in immunocompetent chronic hepatitis B. J Hepatol 26:1393-1395.
14. Hoofnagle JH, Di Bisceglie AM. 1997. Treatment of chronic viral hepatitis. N Engl J Med 336:347-356.
15. Lai CL, Liaw YF, Leung NW, Deslauriers M, Barnard J, Sanathanan L, Gray DF. 1997. Genotypic resistance to lamivudine in a prospective, placebo-controlled multicentre study in Asia of lamivudine therapy for chronic hepatitis B infection: Incidence, kinetics of emergence, and correlation with disease parameters [abstract]. Hepatology 26:522A.
16. Lai CL, Chien RN, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Wu PC, Dent JC, Barber J, Stephenson SL, Gray DF. 1998. A one year trial of lamivudine for chronic hepatitis B. N Engl J Med 339:61-68.
17. Lee WM. 1997. Hepatitis B virus infection. N Engl J Med 337:1733-1745.
18. Leung NW, Lai CL, Chang TT, Guan R, Lee CM, Ng KY, Wu PC. 1999. Three year lamivudine therapy in chronic HBV [abstract]. J Hepatol 30:59.
19. Liaw YF, Chien RN, Yeh CT, Tsai SL, Chu CM. 1999. Acute exacerbation and hepatitis B virus clearance after emergence of YMDD motif mutation during lamivudine therapy. Hepatology 30:567-572.
20. Liaw YF, Leung NW, Chang TT, Guan R, Tai DI, Ng KY, Chien RN, Dent J, Roman L, Edmundson S, Lai CL. 2000. Effects of extended lamivudine therapy in Asian patients with chronic hepatitis B. Gastroenterology 119:172-180.
21. Lin X, Yuan ZH, Wu L, Ding JP, Wen YM. 2001. A single amino acid in the reverse transcriptase domain of hepatitis B virus affects virus replication efficiency. J Virol 75:11827-11833.
22. Lindh M, Andersson AS, Gusdal A. 1997. Genotypes, nt 1858 variants, and geographic origin of hepatitis B virus-large-scaled analysis using a new genotyping method. J Infect Dis 175:1285-1293.
23. Ling R, Harrison TJ. 1999. Functional analysis of mutations conferring lamivudine resistance on hepatitis B virus. J Gen Virol 80:601-606.
24. Ling R, Mutimer D, Ahmed M, Boxall EH, Elias E, Dusheiko GM, Harrison TJ. 1996. Selection of mutations in the hepatitis B virus polymerase during therapy of transplant recipients with lamivudine. Hepatology 3:711-713.
25. Melegari M, Scaglioni PP, Wands JR. 1998. Hepatitis B virus mutants associated with 3TC and famciclovir administration are replication defective. Hepatology 27:628-633.
26. Naoumov NV, Smih C, Williams R. 1996. Emergence and characterization of lamivudine resistant hepatitis B virus variant [abstract]. Hepatology 24:282A.
27. Niesters HG, Honkoop P, Haagsma EB, de Man RA, Schalm SW, Osterhaus AD. 1998. Identification of more than one mutation in the hepatitis B virus polymerase gene arising during prolonged lamivudine treatment. J Infect Dis 177:1382-1385.
28. Ono-Nita SK, Kato N, Shiratori Y, Lan KH, Yoshida H, Carrilho FJ, Omata M. 1999a. Susceptibility of lamivudine-resistant hepatitis B virus to other reverse transcriptase inhibitors. J Clin Invest 103:1635-1640.
29. Ono-Nita SK, Kato N, Shiratori Y, Masaki T, Lan KH, Carrilho FJ, Omata M. 1999b. YMDD motif in hepatitis B virus DNA polymerase influences on replication and lamivudine resistance: A study by in vitro full-length viral DNA transfection. Hepatology 29:939-945.
30. Perrillo R, Rakela J, Dienstag J, Levy G, Martin P, Wright T, Caldwell S, Schiff E, Gish R, Villeneuve JP, Farr G, Anschuetz G, Crowther L, Brown N. 1999. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group. Hepatology 29:1581-1586.
31. Perrillo RP, Lai CL, Liaw YF, Dienstag JL, Schiff ER, Schalm SW, Heathcote EJ, Brown NA, Atkins M, Woessner M, Gardner SD, Perrillo RP. 2002. Predictors of HBeAg loss after lamivudine treatment for chronic hepatitis B. Hepatology 36:186-194.
32. Schalm SW. 1997. Clinical implications of lamivudine resistance by HBV. Lancet 9044:3-4.
33. Schalm SW, Thomas HC, Hadziyannis SJ. 1990. Chronic hepatitis B. In: Popper H, Schaffner FM, editors. Progress in liver disease. New York: Saunders. pp 443-462.
34. Schalm SW, Heathcote J, Cianciara J, Farrell G, Sherman M, Willems B, Dhillon A, Moorat A, Barber J, Gray DF. 2000. Lamivudine and alpha Interferon combination treatment of patients with chronic hepatitis B infection: A randomized trial. Gut 46:562-568.
35. Stuyver LJ, Locarnini SA, Lok A, Richman DD, Carman WF, Dienstag JL, Schinazi RF. 2001. Nomenclature for antiviral-resistant human hepatitis B virus mutations in the polymerase region. Hepatology 33:751-757.
36. Tassopoulos NC, Volpes R, Pastore G, Heathcote J, Buti M, Goldin RD, Hawley S, Barber J, Condreay L, Gray DF. 1999. Efficacy of lamivudine in patients with hepatits B e antigen-negative/hepatitis B virus DNA-positive (precore mutant) chronic hepatitis B. Hepatology 29:889-896.
37. Tipples GA, Ma MM, Fischer KP, Bain VG, Kneteman NM, Tyrell DL. 1996. Mutations in HBV RNA-dependent DNA polymerase confers resistance to lamivudine in vivo. Hepatology 3:714-717.
38. Wang JH, Lu SN, Lee CM, Lee JF, Chou YP. 2002. Fatal hepatic failure after emergence of the hepatitis B virus mutant during lamivudine therapy in a patient with liver cirrhosis. Scand J Gastroenterol 37:366-369.
39. Xiong X, Flores C, Yang H, Toole JJ, Gibbs CS. 1998. Mutations in hepatitis B DNA polymerase associated with resistance to lamivudine do not confer resistance to adefovir in vitro. Hepatology 28:1669-1673.
40. Zollner B, Petersen J, Puchhammer-Stockl E, Kletzmayr J, Sterneck M, Fischer L, Schroter M, Laufs R, Feucht HH. 2004. Viral features of lamivudine resistant hepatitis B genotypes A and D. Hepatology 39:42-50.